On Monday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Rock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI), Canadian Solar Inc. (NASDAQ:CSIQ), C&J Energy Services Ltd. (NYSE:CJES), Synthetic Biologics Inc. (NYSEMKT:SYN)
Rock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI), with shares declined -0.99%, closed at $0.100.
Canadian Solar Inc. (NASDAQ:CSIQ), with shares dropped -3.94%, settled at $33.12.
C&J Energy Services Ltd. (NYSE:CJES), with shares dipped -3.94%, and closed at $11.45.
Synthetic Biologics Inc. (NYSEMKT:SYN), plummeted -1.29%, and closed at $2.29.
Latest NEWS regarding these Stocks are depicted underneath:
Rock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI)
Formerly on March 12, Rock Creek Pharmaceuticals, Inc. (RCPI), filed its annual report on Form 10-K with the Securities and Exchange Commission and offered an update on its drug development activities.
Dr. Michael Mullan, CEO of Rock Creek Pharmaceuticals, commented, “2014 was a period of noteworthy transformation as we embarked on a new strategy to advance our lead candidate, Anatabine Citrate, into human clinical development following formal regulatory protocols both in the United States and Europe. We have transformed Rock Creek Pharmaceuticals into a clinical stage corporation and realigned our corporate facilities and personnel.”
The Corporation’s annual meeting will be held on April 10, 2015 in Sarasota, Florida and will be accessible through a live webcast. In addition to the conduct of corporate matters at that meeting, the Corporation will hold a shareholder vote to conduct a reverse split at an appropriate ratio to insure compliance with NASDAQ minimum bid listing rules, and to maintain the Corporation’s Nasdaq listing. Further, the Corporation will provide commentary on its regulatory strategy and ongoing drug development initiatives designed to advance its lead compound through Phase I and into Phase II trials.
Rock Creek Pharmaceuticals, Inc., a pharmaceutical corporation, focuses on the research, development, and commercialization of compounds and formulations targeting inflammatory and neurological disorders.
Canadian Solar Inc. (NASDAQ:CSIQ)
Canadian Solar Inc. (CSIQ), declared the sale of the 10 MW AC GoldLight solar power plant to an associate of DIF Infrastructure III. This solar power plant is valued at over CAD$68 million (US$54 million) and uses about 46,800 of Canadian Solar’s CSX6-300|305|310P panels. The GoldLight plant is located in the Town of Georgina, Ontario, Canada. It reached commercial operation on January 30, 2015, and will sell electricity following a 20-year Ontario Power Authority feed-in tariff contract.
“The GoldLight project represents another attractive addition to DIF’s growing portfolio of North American renewable energy projects. DIF’s relationship with Canadian Solar has been a key contributor to our expansion,” said Paul Huebener, Head of DIF Americas.
Canadian Solar Inc., together with its auxiliaries, designs, develops, manufactures, and sells solar wafers, cells, and solar module products worldwide. The corporation operates in two segments, Module and Project. Its products comprise various solar modules that are used in residential, commercial, and industrial solar power generation systems.
C&J Energy Services Ltd. (NYSE:CJES)
C&J Energy Services Ltd. (CJES), declared the completion of the combination of C&J with Nabors’ completion and production services business. The resulting combined corporation, which has been renamed C&J Energy Services Ltd. (“New C&J”), is one of the largest completion and production services providers in North America led by the current C&J administration team, with Josh Comstock serving as Chief Executive Officer and Chairman of the Board, and Randy McMullen serving as President and Chief Financial Officer. New C&J is headquartered in Bermuda and its ordinary shares have been listed on the NYSE under the ticker symbol “CJES”. Nabors received about $688 million in cash from C&J as a portion of the consideration for the transaction and now owns about 53% of the outstanding and issued ordinary shares of New C&J, with the remainder held by former C&J shareholders.
C&J Energy Services, Ltd. provides well construction, well completions, and well services to the oil and gas industry in North America. The corporation’s Completion Services segment offers stimulation services, counting fracturing and acidizing to enhance the flow of oil and natural gas from producing zones; cementing services; down-hole surveying services; and coiled tubing services.
Synthetic Biologics Inc. (NYSEMKT:SYN)
Synthetic Biologics Inc. (SYN), declared the initiation of a Phase 2a clinical trial to evaluate the gastrointestinal (GI) antibiotic-degrading effects and the safety of SYN-004, the Corporation’s investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent C. difficile infection (CDI). C. difficile is the leading type of hospital attained infection and is frequently associated with intravenous (IV) antibiotic treatment. Beta-lactam antibiotics are a mainstay in hospital infection administration, and comprise ordinarily used penicillin and cephalosporin antibiotics, such as ceftriaxone.
“We are excited to start our Phase 2a trial of SYN-004 on plan. Synthetic Biologics believes SYN-004 holds the potential to protect the microbiome from the damaging effects of antibiotics and dramatically reduce C. difficile infections through prevention vs. treatment,” said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. “We anticipate reporting topline results from this Phase 2a clinical trial during the second quarter of 2015, and initiating the Phase 2b clinical trial in the second half of this year.”
Synthetics Biologics, Inc., a biotechnology corporation, focuses on development of novel anti-infective biologics and drug candidates targeting specific pathogens that cause serious infections and other diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
